Table 1 Clinical features of 37 aggressive B-cell NHL with overlapping features between DLBCL and BL according to MYC-R status.
From: MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma
n = 37 | MYC-non-R n = 15 (41%) | MYC-R n = 22 (59%) | P-valuea | |
|---|---|---|---|---|
Sex | 0.7 | |||
Female | 10 (27%) | 5 (33%) | 5 (23%) | |
Male | 27 (73%) | 10 (67%) | 17 (77%) | |
Mean age at diagnosis (range) | 13 (3–33) | 15 (8–33) | 11 (3–29) | 0.017 |
Age Group | 0.4 | |||
Children | 32 (86%) | 12 (80%) | 20 (91%) | |
Young Adults | 5 (14%) | 3 (20%) | 2 (9%) | |
Mean months of follow-up (range) | 46 (1–277) | 66 (1–277) | 33 (1–123) | 0.5 |
Stageb | 0.14 | |||
I–II | 11 (30%) | 7 (47%) | 4 (18%) | |
III–IV | 25 (67%) | 9 (53%) | 17 (77%) | |
Unknown | 1 (3%) | - | 1 (5%) | |
Extranodal involvement | 0.7 | |||
Yes | 25 (68%) | 11 (73%) | 14 (64%) | |
No | 12 (32%) | 4 (27%) | 8 (36%) | |
Gastrointestinal location | 0.5 | |||
Yes | 15 (41%) | 7 (47%) | 8 (36%) | |
No | 22 (59%) | 8 (53%) | 14 (64%) | |
Treatment strategy | 0.9 | |||
BFM-Based | 2 (5%) | 1 (7%) | 1 (5%) | |
Burkimab | 1 (3%) | - | 1 (5%) | |
CHOP | 3 (8%) | 2 (13%) | 1 (5%) | |
LMB-Based | 31 (84%) | 12 (80%) | 19 (85%) | |
Rituximab at first-line therapy | 0.6 | |||
Yes | 14 (38%) | 5 (33%) | 9 (41%) | |
No | 23 (62%) | 10 (67%) | 13 (59%) | |
LDH levels | 0.14 | |||
High | 12 (40%) | 3 (20%) | 9 (41%) | |
Normal | 18 (60%) | 11 (67%) | 8 (36%) | |
Unknown | 7 | 2 (13%) | 5 (23%) | |
Hematopoietic stem cell transplantation | >0.9 | |||
Yes | 2 (5%) | 1 (7%) | 1 (5%) | |
No | 31 (84%) | 13 (86%) | 18 (82%) | |
Unknown | 4 (11%) | 1 (7%) | 3 (13%) | |
Relapse | >0.9 | |||
Yes | 5 (14%) | 2 (13%) | 3 (14%) | |
No | 32 (86%) | 14 (87%) | 18 (86%) | |
Status | 0.063 | |||
Deceasedc | 6 (16%) | - | 6 (29%) | |
Alive | 31 (84%) | 16 (100%) | 15 (71%) |
